Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 1.1% during mid-day trading on Thursday . The company traded as low as $8.25 and last traded at $8.26. 579,270 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 6,160,666 shares. The stock had previously closed at $8.35.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th.

Recursion Pharmaceuticals Stock Down 5.7 %

The business has a 50-day moving average price of $8.69 and a two-hundred day moving average price of $9.73. The firm has a market cap of $1.87 billion, a PE ratio of -5.00 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.34) earnings per share. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total value of $91,003.65. Following the completion of the transaction, the director now owns 7,218,414 shares in the company, valued at $57,386,391.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total transaction of $91,003.65. Following the completion of the sale, the director now owns 7,218,414 shares in the company, valued at $57,386,391.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the sale, the chief executive officer now owns 863,524 shares of the company’s stock, valued at approximately $6,675,040.52. The disclosure for this sale can be found here. Insiders sold 249,235 shares of company stock worth $2,009,063 over the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in RXRX. Midwest Financial Group LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth about $90,000. SteelPeak Wealth LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth about $161,000. 180 Wealth Advisors LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth about $134,000. SG Americas Securities LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth about $192,000. Finally, Gilman Hill Asset Management LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth about $101,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.